Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Merger or Acquisition (December 2022)
6 slides from Therapeuticsmd's merger presentation, Dec 5, 2022
Slide 1: Strategic Transformational Transaction Update
Strategic Transformational Transaction Update December 5, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as “we,” “our,” or the “Company”) may contain forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the proposed transaction, expectations with regard to the finan
Slide 3: Transformational Transaction
Transformational Transaction Transaction between TherapeuticsMD (“TXMD”) and Mayne Pharma Group Limited (“Mayne Pharma”) transforms TXMD into a pharmaceutical royalty company Mayne Pharma (ASX: MYX) is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic phar
Slide 4: TherapeuticsMD will have Sufficient Cash to Fund Operations
TherapeuticsMD will have Sufficient Cash to Fund Operations Company projected to have an estimated $8 - 9mm of cash at year-end prior to anticipated transaction close Company estimates $15 - 16mm of net proceeds from the transaction* Reflects $153mm upfront payment less repayment of funded debt, red
Slide 5: Attractive Royalty Agreement with Meaningful Revenue Upside Potential
Attractive Royalty Agreement with Meaningful Revenue Upside Potential Quarterly royalty revenue stream with upside for shareholders to participate in growth in revenue of licensed and transferred products Illustrative annual royalty stream of ~$7mm assuming LTM level of net product sales One-time mi
Slide 6: Preliminary Pro Forma Operational Structure
Preliminary Pro Forma Operational Structure Committed to maximizing post-transaction value through operational efficiency Minimal headcount to support transformed business model Anticipated reduction in the number of Board of Directors No debt or preferred equity post-closing
TherapeuticsMD — Merger or Acquisition (December 2022) on 6ix